Abstract

Population genomics is increasingly positioned as a transformative approach for identifying and managing 
monogenic disorders at scale through systematic analysis of genomic variation within populations. Sickle cell 
disease (SCD), a globally prevalent hemoglobinopathy with well-defined genetic etiology and significant public 
health burden, represents a strong candidate for population-based genomic screening programs. This paper 
examines the implementation of population genomics for SCD with emphasis on three core components: return of 
results, cascade testing, and health system readiness, while critically engaging with equity, ethical, legal, and social 
implications.The return of genomic results raises challenges related to timing, communication strategies, and 
health literacy, particularly in settings with limited genetic counseling infrastructure. Cascade testing emerges as a 
cost-effective and preventive strategy for identifying at-risk relatives, but its success depends on effective family 
communication pathways and culturally sensitive consent processes. Health system readiness is essential for 
sustainable implementation and requires robust infrastructure, workforce capacity, data governance systems, and 
integration with clinical workflows and electronic health records. Equity considerations remain central, as 
disparities in access to testing, interpretation, and follow-up care may exacerbate existing health inequalities if not 
carefully addressed. Community engagement, trust-building, and participatory governance are essential for ethical 
implementation and long-term sustainability. Ultimately, population genomics for SCD offers significant promise 
for precision public health, but its success depends on balancing technological capability with ethical 
responsibility, system capacity, and equitable access.